- Experience of 1 case on the intervention effect of individualized rehabilitation exercise on bone and joint pain symptoms caused by taking anastrozole. [Letter]Asian J Surg. 2023 Feb 01 [Online ahead of print]AJ
- Publisher Full Text (DOI)
- Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer. [Journal Article]Plast Reconstr Surg. 2022 Dec 21 [Online ahead of print]PR
- CONCLUSIONS: Patients receiving AI therapy have an increased incidence of trigger finger. The outcomes of treatment is equivalent between AI and non-AI trigger finger populations. However, patients that require switching of regimens due to significant musculoskeletal symptoms are more likely to fail steroid therapy. Poorly controlled diabetes was also an independent factor for compromised steroid treatment of trigger finger.
- Publisher Full Text (DOI)
- [A real-world study of the effects of endocrine therapy on liver function in breast cancer]. [Journal Article]Zhonghua Wai Ke Za Zhi. 2023 Feb 01; 61(2):107-113.ZW
- Objective: To compare the effect of different endocrine therapy drugs on liver function in patients with early breast cancer. Methods: A retrospective cohort study was conducted to include 4 318 patients with early breast cancer who received adjuvant endocrine therapy in Department of Breast Surgery, Peking Union Medical College Hospital from January 1, 2013 to December 31, 2021. All the patients…
- Publisher Full Text (DOI)
- Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis. [Journal Article]Clin Cancer Res. 2023 Jan 30 [Online ahead of print]CC
- CONCLUSIONS: The PFS benefit of pertuzumab was maintained and OS was similar between arms at final analysis. Adding pertuzumab may enhance activity in patients who do not require first-line chemotherapy for M/LABC. No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.
- Publisher Full Text (DOI)
- Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review. [Review]JCO Glob Oncol. 2023 Jan; 9:e2100289.JG
- CONCLUSIONS: The evidence mapped from studies that evaluated OAM adherence in women with BC indicates that nonadherence to OAMs is common. Applying context-specific standardized measures to assess adherence and facilitators or strategies targeting the identified barriers can optimize adherence and treatment outcomes. Effective interventions to improve adherence are limited. Therefore, further empirical and interventional studies in Africa are required to enhance the evidence.
- Publisher Full Text (DOI)
- Low-Grade Serous Ovarian Carcinoma: a Retrospective Study from a Tertiary Cancer Institute. [Journal Article]
- The aim of this study was to evaluate the clinico-pathological behaviour and treatment patterns of low-grade serous carcinomas (LGSC) of ovary treated at a regional cancer centre. A retrospective analysis was done for the histopathology-proven cases of low-grade serous ovarian carcinoma, treated at a tertiary cancer institute between January, 2010, and September, 2019. There were 28 patients iden…
- Publisher Full Text (DOI)
- Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. [Journal Article]Ann Surg Oncol. 2023 Jan 18 [Online ahead of print]AS
- CONCLUSIONS: Rarely does NAI result in pCR for patients with stage 2 or 3 ER+ BC. However, a significant proportion will have downstaged to allow for BCS. Local-regional recurrence after surgery is uncommon (1.5% at 5 years), supporting the use of BCS after NAI.
- Publisher Full Text (DOI)
- Price, Availability and Affordability of Anti-Cancer Medicines in Addis Ababa, Ethiopia. [Journal Article]
- CONCLUSIONS: Medicines for cancer treatment are unavailable and the few available medicines are unaffordable in Addis Ababa, Ethiopia. Different interventions should be done to improve access to cytotoxic medications.
- PMC Free PDF
- Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. [Randomized Controlled Trial]Eur J Cancer. 2023 Feb; 180:108-116.EJ
- CONCLUSIONS: Comparable to efforts to de-escalate treatment duration in metastatic bone disease, there was no evidence to indicate that a reduced number of zoledronate infusions is associated with reduced adjuvant efficacy. Further studies to define optimal regimens of adjuvant bone-targeted therapies are required.
- Publisher Full Text (DOI)
- The integrative bioinformatics approaches to predict the xanthohumol as anti-breast cancer molecule: Targeting cancer cells signaling PI3K and AKT kinase pathway. [Journal Article]
- CONCLUSIONS: The finding revealed the ability of xanthohumol to bind with multiple cancer cell signaling molecules including PI3K, AKT kinase, and HER2. The current novel study opened the door to advancing research into the management and treatment of breast cancer.
- PMC Free PDF
- Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older. [Journal Article]Int J Radiat Oncol Biol Phys. 2022 Dec 28 [Online ahead of print]IJ
- CONCLUSIONS: U-WBI alone appears the more cost-effective de-escalation strategy for these low-risk patients, compared with AI alone. Combining U-WBI and AI appears more costly but may be preferred by some patients.
- Publisher Full Text (DOI)
- 17beta-estradiol alleviates contusion-induced skeletal muscle injury by decreasing oxidative stress via SIRT1/PGC-1α/Nrf2 pathway. [Journal Article]Steroids. 2022 Dec 24; 191:109160.S
- CONCLUSIONS: Our results suggest that E2 is a positive intervention factor for muscle repair followed contusion-induced myoinjury, through its effects on suppressing oxidative stress via activating the SIRT1/PGC-1α/Nrf2 pathway.
- Publisher Full Text (DOI)
- iPSCs-derived mesenchymal stromal cells mitigate anxiety and neuroinflammation in aging female mice. [Journal Article]Int J Biochem Cell Biol. 2023 Feb; 155:106347.IJ
- Perimenopause is a natural transition to menopause, when hormone disturbance can result in both short-term mental disorders, such as anxiety, and long-term neuroinflammation due to blood-brain barrier (BBB) impairment, which may lead to more serious neurological disorders later on, such as dementia. Effective treatments may prevent both short-term and long-term neurological sequela, which formed …
- Publisher Full Text (DOI)
- Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review. [Case Reports]
- Cystic brain metastases (CBM) in patients with breast cancer are rare. They have a worse prognosis than solid brain metastases, and they are less sensitive to radiotherapy. We report a case of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer with CBM. The patient underwent treatment with docetaxel combined with capecitabine for 5 m…
- PMC Free PDF
- Update on new treatments for rare ovarian tumours. [Review]
- CONCLUSIONS: The last few years have exhibited a paradigm shift towards the possibility to develop dedicated trials for ROT, owing to international collaborations supported by institutional networks. Current trials, molecular-driven and based on innovative designs, are highly promising, as they may bring ROT management towards more personalized medicine.
- PMC Free PDF
- A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens. [Journal Article]Clin Transl Sci. 2022 Nov 23 [Online ahead of print]CT
- Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapolation from a noncompartmental analysis (NCA) with a two-fold acceptance criterion between pharmacokinetic metrics of the extrapolated microdose and the therapeut…
- Publisher Full Text (DOI)
- [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report]. [Case Reports]Gan To Kagaku Ryoho. 2022 Nov; 49(11):1271-1273.GT
- A 49-year-old woman presented with abdominal pain. A computed tomography scan revealed a left breast mass with suspected peritoneal dissemination. She had no notable family history of the disease. Following a detailed examination, she was diagnosed with ovarian cancer(Stage ⅢC)and left breast cancer(Stage Ⅰ). After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant…
- Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. [Journal Article]
- Resistance of advanced hormone-dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the progression-free rate compared to Anastrozole alone. However, a better patient selection based on biomarkers would improve patient outcome. We evalu…
- PMC Free PDF
- Effect of Aromatase Inhibitors on Serum Calprotectin Levels in an Animal Experimental Model: Trial. [Journal Article]
- CONCLUSIONS: The potential of hepatotoxicity can be examined by assessing the elevation of inflammation markers such as Calprotectin, which is an indicator that should be strictly taken into consideration when administering aromatase inhibitors as treatment.
- PMC Free PDF
- Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. [Journal Article]
- This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) without prior CDK4 and 6 inhibitor exposure. Patients were divided into two cohorts: treat…
- PMC Free PDF
- Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors. [Journal Article]
- CONCLUSIONS: The non-inferiority of NHT in relation to NCT will provide further evidence that replacing NCT with NHT is safe and effective in eligible patients, which is particularly relevant for populations with limited access to health services and for institutions with few available resources.
- PMC Free PDF
- Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study. [Review]
- This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for publi…
- PMC Free PDF
- Theoretical Study on the Aggregation and Adsorption Behaviors of Anticancer Drug Molecules on Graphene/Graphene Oxide Surface. [Journal Article]
- Graphene and its derivatives are frequently used in cancer therapy, and there has been widespread interest in improving the therapeutic efficiency of targeted drugs. In this paper, the geometrical structure and electronic effects of anastrozole(Anas), camptothecin(CPT), gefitinib (Gefi), and resveratrol (Res) on graphene and graphene oxide(GO) were investigated by density functional theory (DFT) …
- PMC Free PDF
- 27-Hydroxycholesterol-Induced Dysregulation of Cholesterol Metabolism Impairs Learning and Memory Ability in ApoE ε4 Transgenic Mice. [Journal Article]
- Dysregulated brain cholesterol metabolism is one of the characteristics of Alzheimer's disease (AD). 27-Hydroxycholesterol (27-OHC) is a cholesterol metabolite that plays an essential role in regulating cholesterol metabolism and it is suggested that it contributes to AD-related cognitive deficits. However, the link between 27-OHC and cholesterol homeostasis, and how this relationship relates to …
- PMC Free PDF
- Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers. [Journal Article]
- The molecular classification of breast cancer (BC) dictates pharmacological treatment. Estrogen receptor α (ERα) expressing tumors are treated with 4OH-tamoxifen or fulvestrant, which inhibits the receptor, or with aromatase inhibitors (i.e., anastrozole, letrozole, and exemestane) that reduce the 17β-estradiol (E2) circulating blood levels. Besides such endocrine therapy (ET) drugs, ERα-positive…
- PMC Free PDF
- The efficacy of anastrozole in subfertile men with and without abnormal testosterone to estradiol ratios. [Journal Article]
- CONCLUSIONS: The majority of subfertile men with and without abnormal T/E2 ratios responded to anastrozole treatment with significantly improved semen parameters and sex hormone levels. Anastrozole showed potential effectiveness in male subfertile patients with T/E2 >10, to be confirmed by future prospective, randomized, controlled studies.
- PMC Free PDF
- Escitalopram co-prescription in anastrozole-treated breast cancer patients. [Journal Article]
- CONCLUSIONS: Escitalopram co-prescription resulted in significant increase in plasma anastrozole levels without affecting the serum estradiol levels. Our findings emphasize the need for close monitoring in case of concomitant use of anastrozole and escitalopram, especially in obese patients and the potential role of therapeutic drug monitoring.
- PMC Free PDF
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. [Randomized Controlled Trial]
- In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and…
- Publisher Full Text (DOI)
- Efficacy of aromatase inhibitor therapy in a case with large cell calcifying Sertoli cell tumour-associated prepubertal gynaecomastia. [Case Reports]J Pediatr Endocrinol Metab. 2022 Dec 16; 35(12):1565-1570.JP
- CONCLUSIONS: Testicular tumour should be investigated in a patient with PJS who presents with prepubertal gynaecomastia. When findings are consistent with LCCSCT, aromatase inhibitors may be preferred in the treatment.
- Publisher Full Text (DOI)
- The effect of aromatase inhibitors against possible testis toxicity in pembrolizumab treated rats. [Journal Article]Andrologia. 2022 Nov; 54(10):e14557.A
- Pembrolizumab is a monoclonal antibody. Anastrozole is an infertility inhibitor of aromatase. Resveratrol is an antioxidant polyphenol in the reproductive system. This study was planned to demonstrate the protective effects of anastrozole and resveratrol against pembrolizumab-induced reproductive damage. Forty-two Sprague-Dawley rats were used in the study. Groups: The control, Pembrolizumab (PEM…
- Publisher Full Text (DOI)